I have been prescribed ZEPOSIA.
Important Contact Information

My healthcare professional who prescribed ZEPOSIA:

Name: _____

Office phone number: _____

Institution address: _____

_____

2084-IL-2100005

This Card content was approved according to the guidelines of the ministry of health on 13 May 2021

ZEPOSIA® (ozanimod)
Pregnancy Reminder Card

(For women of childbearing potential)

Bristol Myers Squibb™

2084-IL-2100005

This Card content was approved according to the guidelines of the ministry of health on 13 May 2021

Patient Information

If used during pregnancy, ZEPOSIA® (ozanimod) can harm the unborn baby. Potential risks include loss of the unborn baby and birth defects.

- Do not use ZEPOSIA® if you are pregnant or breast-feeding, or could become pregnant and are not using effective birth control.
- Before starting treatment with ZEPOSIA®:
  1. Your prescriber will explain the potential risks to an unborn baby if you become pregnant while taking ZEPOSIA® and will regularly inform you how to minimize the risks.
  2. You must use effective birth control while taking ZEPOSIA® and for 3 months after you stop taking ZEPOSIA®.
  3. You must have a negative pregnancy test verified by your prescriber and repeated at suitable intervals.
- If you become pregnant while on treatment, ZEPOSIA® must be stopped. Your doctor will advise you of the harmful effects to the baby associated with ZEPOSIA® treatment and ultrasound exams should be performed.

- You should stop taking ZEPOSIA® 3 months before planning a pregnancy.

- If you stop taking ZEPOSIA®, tell your doctor right away if your multiple sclerosis symptoms get worse as there is a possibility that the disease may return.

- Tell your doctor right away if you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby.

Please see the back of this reminder card for your prescriber's contact information.

For more information about the effects and side effects of ZEPOSIA®, please refer to the Patient Information Leaflet for ZEPOSIA®.

For more information please contact your doctor or pharmacist. You can report side effects directly to the Israeli Ministry of Health by using the on-line form for reporting adverse events on the Home page of the Ministry of health website: www.health.gov.il
or by entering the following link: https://sideeffects.health.gov.il

To obtain a copy of this document please contact Bristol-Myers Squibb
by phone: 03-5231021 or fax: 03-9226896.

Bristol Myers Squibb™

2084-IL-2100005